Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: A tool for the standardization of rat in situ intestinal permeability studies

Journal of Pharmaceutical and Biomedical Analysis

Volumn 43, Issue 4, 2007, Pages 1546-1551

  Venkatesh, Gantala ^a   Ramanathan, S ^a   Mansor, S M ^a   Nair, N K ^a   Sattar, Munavvar Abdul ^b   Croft, Simon L ^c   Navaratnam, V ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

^b SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^c Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

Atenolol; Buparvaquone; In situ intestinal permeability; P glycoprotein; Propranolol; Quinidine; RP HPLC; Verapamil

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; ATENOLOL; BUPARVAQUONE; PROPRANOLOL; QUINIDINE; VERAPAMIL;

ARTICLE; CORRELATION COEFFICIENT; DRUG DETERMINATION; DRUG PENETRATION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIPROTOZOAL AGENTS; ATENOLOL; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; MALE; MOLECULAR STRUCTURE; NAPHTHOQUINONES; PERFUSION; PERMEABILITY; PROPRANOLOL; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; VERAPAMIL;

EID: 33847095139     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.11.013     Document Type: Article

References (17)

1. Li A.P. Drug Discov. Today: Technol. 2 (2005) 179-185
2. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. Pharm. Res. 12 (1995) 413-420
3. Hamalainen M.D., and Karlsson A.F. Drug Discov. Today: Technol. 1 (2004) 397-405
4. Hidalgo I.J. Curr. Top. Med. Chem. 1 (2001) 385-401
5. Kumar T.R.S., Chawla S., Nachaegari S.K., Singh S.K., and Srinivas N.R. J. Pharm. Biomed. Anal. 38 (2005) 173-179
6. Chawla S., Ghosh S., Sihorkar V., Nellore R., Kumar T.R.S., and Srinivas N.R. Biomed. Chromatogr. 20 (2006) 349-357
7. Varma M.V.S., Kapoor N., Sarkar M., and Panchagnula R. J. Chromatogr. B 813 (2004) 347-352
8. Varma M.V.S., Sarkar M., Kapoor N., and Panchagnula R. J. Chromatogr. B 816 (2005) 243-249
9. Varma M.V.S., Sateesh K., and Panchagnula R. Mol. Pharm. 2 (2005) 12-21
10. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000,CDER/FDA.
11. Vexenat J.A., Croft S.L., Campos J.H.F., and Miles M.A. Vet. Parasitol. 77 (1998) 71-73
12. Mantyla A., Garnier T., Rautio J., Nevalainen T., Vepsalainen J., Koskinen A., Croft S.L., and Tomijarvinen. J. Med. Chem. 47 (2004) 188-195
13. Mantyla A., Rautio J., Nevalainen T., Vepsalainen J., Juvonen R., Kendrick H., Garnier T., Croft S.L., and Jarvinen T. Bioorg. Med. Chem. 12 (2004) 3497-3502
14. Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., Gonzalez I., Fernandez C., Sanchez G., Garrigues T.M., and Merino V. Eur. J. Pharm. Sci. 21 (2004) 429-441
15. Sutton S.C., Rinaldi M.T.S., and Vukovinsky K.E. AAPS Pharm. Sci. 3 (2001) 1-5
16. Varma M.V.S., and Panchagnula R. Eur. J. Pharm. Sci. 25 (2005) 445-453
17. Issa C., Gupta P., and Bansal A.K. AAPS Pharm. Sci. Technol. 4 (2003) 1-5